MX350689B - Proteinas env lentivirales mutadas y su uso como farmacos. - Google Patents

Proteinas env lentivirales mutadas y su uso como farmacos.

Info

Publication number
MX350689B
MX350689B MX2014006744A MX2014006744A MX350689B MX 350689 B MX350689 B MX 350689B MX 2014006744 A MX2014006744 A MX 2014006744A MX 2014006744 A MX2014006744 A MX 2014006744A MX 350689 B MX350689 B MX 350689B
Authority
MX
Mexico
Prior art keywords
lentiviral env
drugs
mutated lentiviral
env proteins
mutated
Prior art date
Application number
MX2014006744A
Other languages
English (en)
Other versions
MX2014006744A (es
Inventor
Thierry Heidmann
Original Assignee
Viroxis S A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viroxis S A S filed Critical Viroxis S A S
Publication of MX2014006744A publication Critical patent/MX2014006744A/es
Publication of MX350689B publication Critical patent/MX350689B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende, como substancia activa, una proteína ENV lentiviral mutada, substancialmente carente de propiedades inmunosupresoras o una variante de la proteína ENV lentiviral mutada o un fragmento de las proteínas anteriores, en asociación con un portador farmacéuticamente aceptable.
MX2014006744A 2011-12-07 2012-12-07 Proteinas env lentivirales mutadas y su uso como farmacos. MX350689B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11306625 2011-12-07
PCT/EP2012/074835 WO2013083799A1 (en) 2011-12-07 2012-12-07 Mutated lentiviral env proteins and their use as drugs

Publications (2)

Publication Number Publication Date
MX2014006744A MX2014006744A (es) 2014-12-08
MX350689B true MX350689B (es) 2017-09-13

Family

ID=47435901

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006744A MX350689B (es) 2011-12-07 2012-12-07 Proteinas env lentivirales mutadas y su uso como farmacos.

Country Status (16)

Country Link
US (1) US9682137B2 (es)
EP (1) EP2788372B1 (es)
JP (2) JP6415324B2 (es)
KR (1) KR102059918B1 (es)
CN (1) CN104169295B (es)
AU (1) AU2012350258B2 (es)
BR (1) BR112014013704B1 (es)
CA (1) CA2856180C (es)
DK (1) DK2788372T3 (es)
ES (1) ES2748864T3 (es)
IL (1) IL232926B (es)
IN (1) IN2014CN04927A (es)
MX (1) MX350689B (es)
RU (1) RU2654673C2 (es)
WO (1) WO2013083799A1 (es)
ZA (1) ZA201403617B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018322831B2 (en) * 2017-09-01 2023-04-27 Inprother Aps A vaccine for use in the prophylaxis and/or treatment of a disease
WO2022152818A1 (en) 2021-01-13 2022-07-21 Viroxis Measles-hiv or measles-htlv vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201750A1 (en) * 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
US20070054262A1 (en) 2003-03-28 2007-03-08 Baker Denise M Methods of identifying optimal variants of peptide epitopes
JP5060284B2 (ja) * 2004-03-30 2012-10-31 アンスティテュ・グスターブ・ルシ ウイルスタンパク質の免疫抑制作用のモデュレーションに関与するポリペプチド配列
EP2420248A1 (en) 2004-08-17 2012-02-22 Institut Gustave Roussy Mutated HIV NEF for modulating immunity
US20110305749A1 (en) 2008-08-28 2011-12-15 Mogens Ryttergaard Duch HIV-1 Envelope Polypeptides for HIV Vaccine
RU2426788C1 (ru) * 2010-03-01 2011-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ЦНИИЭ Роспотребнадзора) Генетические конструкции для антивич-терапии

Also Published As

Publication number Publication date
BR112014013704A2 (pt) 2021-02-17
MX2014006744A (es) 2014-12-08
EP2788372A1 (en) 2014-10-15
AU2012350258A1 (en) 2014-06-05
KR20140116091A (ko) 2014-10-01
JP2015505836A (ja) 2015-02-26
IL232926B (en) 2019-01-31
DK2788372T3 (da) 2019-10-14
WO2013083799A1 (en) 2013-06-13
CA2856180A1 (en) 2013-06-13
AU2012350258B2 (en) 2017-03-02
US20140294880A1 (en) 2014-10-02
US9682137B2 (en) 2017-06-20
ZA201403617B (en) 2015-07-29
CN104169295B (zh) 2020-07-28
RU2654673C2 (ru) 2018-05-21
CN104169295A (zh) 2014-11-26
KR102059918B1 (ko) 2020-02-11
JP6415324B2 (ja) 2018-10-31
BR112014013704B1 (pt) 2023-01-31
JP2018150370A (ja) 2018-09-27
CA2856180C (en) 2022-09-06
IN2014CN04927A (es) 2015-09-18
IL232926A0 (en) 2014-07-31
RU2014127521A (ru) 2016-02-10
AU2012350258A8 (en) 2014-07-17
ES2748864T3 (es) 2020-03-18
EP2788372B1 (en) 2019-07-10

Similar Documents

Publication Publication Date Title
NZ630542A (en) Methods of treating a tauopathy
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
MY168297A (en) Cytotoxic Peptides and Antibody Drug Conjugates Thereof
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
MX359288B (es) Forma iv del clorhidrato de ivabradina.
UA110103C2 (uk) Модифікований туберкульозний антиген
EA201270722A1 (ru) Формы рифаксимина и их применение
GB201106750D0 (en) Novel compounds
CL2013002474A1 (es) Compuestos derivados de piperidina puenteada (3-aza-biciclo[3.2.1]oct-8-il), moduladores de b-amiloide; procedimiento de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades tales como alzheimer, síndrome de down, entre otras.
EA201390203A1 (ru) Способы получения тубулизинов
MX2013004061A (es) Analogos de ciclosporina.
MX2015001083A (es) Polipeptidos de factor x modificados y usos de los mismos.
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
TR201903026T4 (tr) S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari.
MX2013004062A (es) Analogos de ciclosporina.
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
BR112013033544A2 (pt) dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos
MX2016007682A (es) Composicion farmaceutica que comprende ivabradina amorfa.
EP2654725A4 (en) MICROPARTICLE WITH PHYSIOLOGICALLY ACTIVE PEPTIDE, PROCESS FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH
EA201390950A1 (ru) Гомогенные фармацевтические пероральные лекарственные формы, содержащие лерканидипин и эналаприл или их фармацетически приемлемые соли совместно с органической кислотой
WO2013190509A3 (en) Preparation of intermediates of boceprevir
EA201490041A1 (ru) Пластырь, содержащий диклофенак и тиоколхикозид
NZ631639A (en) Methods and compositions for treating and diagnosing acute myocardial infarction
MX350689B (es) Proteinas env lentivirales mutadas y su uso como farmacos.

Legal Events

Date Code Title Description
FG Grant or registration